Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
Loutfy
Mona R
MR
Immune Deficiency Treatment Centre, Montreal General Hospital, McGill University, Montreal, Que., Canada.
Raboud
Janet M
JM
Walmsley
Sharon L
SL
Saskin
Refik
R
Montaner
Julio S
JS
Hogg
Robert S
RS
Thompson
Courtney A
CA
Harrigan
P Richard
PR
D000328:Adult; D002170:Canada; D015331:Cohort Studies; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D016015:Logistic Models; D061466:Lopinavir; D008297:Male; D015999:Multivariate Analysis; D009154:Mutation; D010641:Phenotype; D011237:Predictive Value of Tests; D011744:Pyrimidinones / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use*; D016879:Salvage Therapy
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D016333:HIV Protease; D019438:Ritonavir